What the 21 October 2026 decision means for medical device and IVD manufacturers
Regulatory Insight | UK Market Access | Michael Murphy PhD, MJ Medica Consulting Ltd
Key update: On 21 October 2026, the UK Government confirmed that CE-marked medical devices and IVDs certified under the EU MDR and EU IVDR will continue to be recognised in Great Britain on an indefinite basis. The decision follows the targeted consultation held between February and April 2026 and removes the prospect of a fixed end-date for recognition of these EU conformity routes in Great Britain.
What has actually been decided?
The Government response confirms three important policy positions for Great Britain:
· CE-marked devices compliant with EU MDR 2017/745 and EU IVDR 2017/746 are to be recognised indefinitely in Great Britain.
· Transitional arrangements for legacy EU MDD devices are intended to be aligned with the corresponding EU transition timelines.
· The proposed separate international reliance route for devices classified higher in Great Britain than in the EU will not be taken forward in the form consulted on.
This is a significant strategic shift. The previous framework treated CE recognition as a transitional measure with defined end dates. The new policy is intended to make CE recognition a long-term feature of the GB regulatory system, alongside the domestic UKCA route.
Important implementation point: the Government has confirmed the policy decision and intends to make legislative changes to implement it. Manufacturers should therefore continue to follow the legally effective transitional arrangements until the relevant legislation is amended and brought into force.
What does this mean for manufacturers?
Area
Practical implication
GB market access
For many manufacturers already CE marked under EU MDR or IVDR, a separate UKCA conformity assessment will not become mandatory solely to maintain long-term GB market access once the new policy is implemented.
Regulatory strategy
EU MDR / IVDR conformity can now be treated as a long-term GB access strategy rather than merely a temporary bridge, subject to implementation of the legislative changes.
UKCA
UKCA remains available as the domestic GB conformity route and is not being abolished.
Legacy MDD devices
The Government intends to align GB transitional acceptance with EU transition timelines, reducing the risk of different cliff-edge dates across GB and EU markets.
UK-specific obligations
CE recognition does not remove domestic GB obligations. Manufacturers must still meet applicable UK requirements, including UK Responsible Person appointment where required, MHRA registration and GB post-market surveillance obligations.
Northern Ireland
The announcement concerns Great Britain. Northern Ireland remains subject to its separate regulatory framework and manufacturers should assess NI market access independently.
Why this matters strategically
For manufacturers, the biggest benefit is regulatory predictability. A company planning an EU MDR or IVDR conformity route can now do so with much greater confidence that the resulting CE marking will continue to support access to England, Scotland and Wales over the long term.
That has several practical consequences:
· Avoiding duplicate conformity-assessment programmes where UKCA would add little additional value to the product strategy.
· Simplifying evidence planning because one core EU technical documentation package can remain central to both EU and GB market access.
· Reducing the likelihood of manufacturers deprioritising Great Britain because of additional approval cost or duplicative regulatory work.
· Giving regulatory teams a clearer basis for long-term portfolio and launch planning across EU and GB markets.
What does not change
Indefinite CE recognition should not be interpreted as deregulation of the GB market. The MHRA remains responsible for oversight of medical devices placed on the GB market, and the Government has explicitly linked the recognition policy to strengthened post-market surveillance and reporting requirements.
· Manufacturers outside the UK still need an appropriately appointed UK Responsible Person where required.
· Devices still need to be registered with the MHRA in accordance with applicable requirements.
· GB vigilance, incident reporting and post-market surveillance obligations continue to apply.
· Manufacturers remain responsible for ensuring that the CE certification relied upon is valid and applicable to the device being placed on the GB market.
· UKCA remains a legitimate domestic route and is being modernised through the wider GB medical-device regulatory reform programme.
The UKCA question
The announcement does not remove UKCA. Instead, it changes the strategic context in which manufacturers decide whether to use it. Where CE marking already provides access to both the EU and, once the policy is implemented, Great Britain, manufacturers will need a clear commercial or regulatory reason to pursue a separate UKCA route.
The Government has also confirmed that the UKCA framework itself is being modernised through the planned pre-market statutory instrument, while future reforms are intended to support more flexible approaches for emerging technologies including software and AI-enabled medical devices.
What should manufacturers do now?
1. Do not prematurely abandon existing GB transition plans until the implementing legislation is in force.
2. Review regulatory strategies that assumed a mandatory future switch from CE marking to UKCA.
3. Confirm that UK Responsible Person, MHRA registration and PMS/vigilance arrangements remain current and adequately controlled.
4. For legacy MDD products, continue tracking both EU and GB transitional rules until the new alignment is legally implemented.
5. Reassess the business case for UKCA where a separate UK conformity route had been planned primarily because CE recognition was expected to expire.
6. Keep Northern Ireland strategy separate from GB because the regulatory basis is different.
MJ Medica perspective
For industry, this is a pragmatic decision. The value of CE recognition is not simply that it reduces paperwork; it lets manufacturers build one coherent evidence strategy around the EU MDR or IVDR and use that conformity route across a larger market without creating a duplicative approval programme for Great Britain.
The most important next step for regulatory teams is therefore not to treat the announcement as “nothing changes”. It should trigger a review of GB market-access assumptions, UKCA plans, legacy-device transition strategies and UK-specific lifecycle controls. The regulatory route may become simpler, but the manufacturer’s domestic responsibilities in Great Britain remain.
Regulatory context
· MHRA / Department of Health and Social Care, “Government confirms indefinite recognition of CE marked medical devices”, published 21 October 2026.
· Government response to the targeted consultation on indefinite recognition of CE marked medical devices, updated 21 October 2026.
· UK Medical Devices Regulations 2002 (SI 2002 No. 618), as amended.
· MHRA guidance on timelines for acceptance of CE-marked medical devices in Great Britain.
Publication note: This article reflects the Government/MHRA position announced on 21 October 2026. The policy requires legislative implementation. Manufacturers should verify the current legally effective requirements and transitional dates before making product-specific regulatory decisions.